{'fraction_non_alphanumeric': 0.02693965517241379, 'fraction_numerical': 0.015086206896551725, 'mean_word_length': 5.1118421052631575, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Protein from Phaleria macrocarpa Fruit Aqueous Extract Inhibits Early and Late Replication Phases of Human Herpes Virus Type-1

Human herpes virus type-1 (HHV-1) or previously known as herpes simplex virus type-1 (HSV-1) is a human virus pathogen causing a diversity of diseases ranging from common cold sores to life-threatening encephalitis1. HHV-1 infection is extremely contagious by direct contact from person to person with the possibility of becoming widespread throughout the world. The major antiviral therapy for HHV is acyclovir (ACV) which is a nucleoside analogue that reduce the severity of the symptoms but does not cure the infection2-3. The emergence of drug-resistant herpes virus strains has been associated with the increasing clinical use of ACV essentially among immunocompromised patients and in neonates1,4,5. Thus, antiviral agent exhibiting new anti-HHV-1 mechanisms is needed to overcome this threat6.